XML 45 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2
SUBSEQUENT EVENT (Notes)
12 Months Ended
Oct. 31, 2016
Subsequent Event [Line Items]  
Subsequent Events [Text Block]
20.   SUBSEQUENT EVENT

On December 19, 2016 we signed an agreement to acquire 100 percent of the stock of Multiplicom NV (“Multiplicom”), a leading European diagnostics company with state-of-the-art genetic testing technology and products, for  approximately €68 million in cash. Multiplicom, headquartered in Belgium, develops, manufactures and commercializes molecular diagnostic assays, provided as kits, which enable personalized medicine. The acquisition is expected to be completed by mid-January, subject to local laws and regulations and customary closing conditions. The financial results of Multiplicom will be included within Agilent's from the date of the close, which is expected to be during the first quarter of 2017.